PMID- 30143818
OWN - NLM
STAT- MEDLINE
DCOM- 20191001
LR  - 20191001
IS  - 1437-160X (Electronic)
IS  - 0172-8172 (Linking)
VI  - 38
IP  - 11
DP  - 2018 Nov
TI  - Long-term etanercept survival in patients with psoriatic arthritis: a multicenter 
      retrospective analysis in daily clinical practice in Spain.
PG  - 2037-2043
LID - 10.1007/s00296-018-4144-8 [doi]
AB  - Although several randomized clinical trials and observational studies have 
      evaluated the effectiveness, safety and drug survival of etanercept (ETN) in the 
      treatment of psoriatic arthritis (PsA), long-term data regarding these aspects 
      are currently scarce. For this reason, we sought to investigate the long-term 
      survival and safety of ETN in PsA patients in 4 tertiary care Spanish hospitals 
      over a 13-year observation period (from 2004 to 2017). The records of 85 PsA 
      patients were reviewed. ETN showed an excellent survival profile, with rates of 
      treatment discontinuation at 1, 3, 5 and 10 years of 15, 37, 46 and 59%, 
      respectively. In our cohort, a trend toward longer drug survival in patients with 
      shorter disease duration and those who were treated with ETN as their first 
      biologic agent was observed. On the other hand, combination therapy with 
      conventional disease-modifying antirheumatic drugs did not provide greater 
      improvement on the long-term drug survival. Only 12% of the patients reported 
      adverse events (AEs) during therapy, being most of them of mild to moderate 
      intensity, and in only 7% AEs led to drug discontinuation. To the best of our 
      knowledge, the present study shows the largest follow-up period of ETN-treated 
      population analyzed in a real-life setting, and these results demonstrate the 
      positive safety profile and long-term effectiveness of this biologic agent in the 
      management of PsA patients.
FAU - Deza, Gustavo
AU  - Deza G
AUID- ORCID: 0000-0001-8641-5327
AD  - Department of Dermatology, Hospital del Mar-Institut Mar d'Investigacions 
      Mediques, Passeig Maritim, 25-29, 08003, Barcelona, Spain.
FAU - Notario, Jaime
AU  - Notario J
AD  - Department of Dermatology, Hospital de Bellvitge, Hospitalet de Llobregat, Spain.
FAU - Ferran, Marta
AU  - Ferran M
AD  - Department of Dermatology, Hospital del Mar-Institut Mar d'Investigacions 
      Mediques, Passeig Maritim, 25-29, 08003, Barcelona, Spain.
FAU - Beltran, Emma
AU  - Beltran E
AD  - Department of Reumatology, Hospital del Mar, Barcelona, Spain.
FAU - Almirall, Miriam
AU  - Almirall M
AD  - Department of Reumatology, Hospital del Mar, Barcelona, Spain.
FAU - Alcala, Rebeca
AU  - Alcala R
AD  - Department of Dermatology, Hospital del Mar-Institut Mar d'Investigacions 
      Mediques, Passeig Maritim, 25-29, 08003, Barcelona, Spain.
FAU - Ruiz-Carrascosa, Jose Carlos
AU  - Ruiz-Carrascosa JC
AD  - Department of Reumatology, Hospital San Cecilio, Granada, Spain.
FAU - Sanchez, Ricardo
AU  - Sanchez R
AD  - Department of Reumatology, Hospital San Cecilio, Granada, Spain.
FAU - Perez, Silvia
AU  - Perez S
AD  - Department of Reumatology, Hospital de Basurto, Bilbao, Spain.
FAU - Garcia-Vivar, Maria Luz
AU  - Garcia-Vivar ML
AD  - Department of Reumatology, Hospital de Basurto, Bilbao, Spain.
FAU - Galindez, Eva
AU  - Galindez E
AD  - Department of Reumatology, Hospital de Basurto, Bilbao, Spain.
FAU - Mora, Maribel
AU  - Mora M
AD  - Department of Reumatology, Hospital de Bellvitge, Hospitalet de Llobregat, Spain.
FAU - Rodriguez, Jesus
AU  - Rodriguez J
AD  - Department of Reumatology, Hospital de Bellvitge, Hospitalet de Llobregat, Spain.
FAU - Gallardo, Fernando
AU  - Gallardo F
AUID- ORCID: 0000-0002-8996-3828
AD  - Department of Dermatology, Hospital del Mar-Institut Mar d'Investigacions 
      Mediques, Passeig Maritim, 25-29, 08003, Barcelona, Spain. 
      93702@parcdesalutmar.cat.
LA  - eng
GR  - WI95272/Pfizer Europe/International
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20180824
PL  - Germany
TA  - Rheumatol Int
JT  - Rheumatology international
JID - 8206885
RN  - 0 (Antirheumatic Agents)
RN  - OP401G7OJC (Etanercept)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antirheumatic Agents/*administration & dosage/adverse effects
MH  - Arthritis, Psoriatic/diagnosis/*drug therapy/immunology
MH  - Drug Administration Schedule
MH  - Etanercept/*administration & dosage/adverse effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Practice Patterns, Physicians'
MH  - Retrospective Studies
MH  - Spain
MH  - Tertiary Care Centers
MH  - Time Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Arthritis
OT  - Etanercept
OT  - Psoriasis
OT  - Psoriatic
OT  - Survival
OT  - TNF-alpha blockers
EDAT- 2018/08/26 06:00
MHDA- 2019/10/02 06:00
CRDT- 2018/08/26 06:00
PHST- 2018/07/11 00:00 [received]
PHST- 2018/08/21 00:00 [accepted]
PHST- 2018/08/26 06:00 [pubmed]
PHST- 2019/10/02 06:00 [medline]
PHST- 2018/08/26 06:00 [entrez]
AID - 10.1007/s00296-018-4144-8 [pii]
AID - 10.1007/s00296-018-4144-8 [doi]
PST - ppublish
SO  - Rheumatol Int. 2018 Nov;38(11):2037-2043. doi: 10.1007/s00296-018-4144-8. Epub 
      2018 Aug 24.